Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

Aim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2) plus selumetinib (mitogen-activated extracellular signal-regulated kinase 1/2 inhibitor) in patients with advanced solid tumors. Methods: This phase 1b, open-label, dose-escalation study (NCT03745989) e...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathis, Anastasios, Tolcher, Anthony W., Wang, Judy S., Renouf, Daniel J., Chen, Lin-Chi, Suttner, Leah H., Freshwater, Tomoko, Webber, Andrea L., Nayak, Tapan, Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289957/
https://www.ncbi.nlm.nih.gov/pubmed/37040046
http://dx.doi.org/10.1007/s10637-022-01326-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289957/
https://www.ncbi.nlm.nih.gov/pubmed/37040046
http://dx.doi.org/10.1007/s10637-022-01326-3

Ejemplares similares